Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial

Mease, P, Coates, LC, Helliwell, PS et al. (14 more authors) (2018) Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial. The Lancet, 392 (10162). pp. 2367-2377. ISSN 0140-6736

Abstract

Metadata

Authors/Creators:
  • Mease, P
  • Coates, LC
  • Helliwell, PS
  • Stanislavchuk, M
  • Rychlewska-Hanczewska, A
  • Dudek, A
  • Abi-Saab, W
  • Tasset, C
  • Meuleners, L
  • Harrison, P
  • Besuyen, R
  • Van der Aa, A
  • Mozaffarian, N
  • Greer, JM
  • Kunder, R
  • Van den Bosch, F
  • Gladman, DD
Copyright, Publisher and Additional Information: © 2018 Elsevier Ltd. All rights reserved. This is an author produced version of a paper published in The Lancet. Uploaded in accordance with the publisher's self-archiving policy.
Dates:
  • Published: 1 December 2018
  • Accepted: 3 October 2018
  • Published (online): 22 October 2018
Institution: The University of Leeds
Academic Units: The University of Leeds > Faculty of Medicine and Health (Leeds) > School of Medicine (Leeds) > Institute of Rheumatology & Musculoskeletal Medicine (LIRMM) (Leeds) > Inflammatory Arthritis (Leeds)
Depositing User: Symplectic Publications
Date Deposited: 15 Nov 2018 15:41
Last Modified: 22 Apr 2019 00:46
Status: Published
Publisher: Elsevier
Identification Number: https://doi.org/10.1016/S0140-6736(18)32483-8

Share / Export

Statistics